Tag: Marika Nestor
AKIR001 study selected as overall featured article
The preclinical study underpinning the clinical development of Akiram Therapeutics’ lead candidate AKIR001, published in The Journal of Nuclear Medicine (JNM), has been selected...
Cohort 2a completed and cohort 2b cleared to start in Phase...
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of cohort 2a in the clinical Phase I trial evaluating the...
Akiram Therapeutics AKIR001 published in The Journal of Nuclear Medicine
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, has announced that data on its CD44v6-targeted radiotherapeutic candidate AKIR001 have been published in...
Akiram Therapeutics research selected as Top Rated Oral Presentations at EANM...
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will contribute to several academic presentations at the EANM Congress 2025 in Barcelona, October...
Akiram’s Phase I clinical trial with AKIR001 progresses to next step
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, has announced the completion of the first cohort in the clinical Phase I trial...
Clinical trial of Akiram’s cancer drug candidate AKIR001
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announced that the first patient has been enrolled in the Phase 1 clinical trial...
Akiram Therapeutics strengthens board with drug development expertise
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, has announced the addition of Anna Törner and Peder Walberg to its board of...